Healthy.io vs Pfizer

Side-by-side comparison of AI visibility scores, market position, and capabilities

Pfizer leads in AI visibility (93 vs 53)
Healthy.io logo

Healthy.io

ChallengerHealthcare

Smartphone-Based Diagnostics

Turns smartphones into clinical-grade diagnostic devices; FDA-cleared for at-home urinalysis (kidney disease), wound care, and UTI testing; $218M raised including $50M Series D in 2023.

AI VisibilityBeta
Overall Score
C53
Category Rank
#272 of 596
AI Consensus
71%
Trend
stable
Per Platform
ChatGPT
48
Perplexity
55
Gemini
48

About

Healthy.io is a digital health company that transforms standard smartphones into clinical-grade medical diagnostic tools using computer vision and colorimetric image analysis. Founded in 2013 and headquartered in Tel Aviv, Israel (with U.S. operations), Healthy.io's core technology enables patients to conduct laboratory-quality tests at home using a companion test strip and the smartphone camera, without any additional hardware. The company's Minuteful Kidney product is FDA-cleared for at-home urine albumin-to-creatinine ratio (ACR) testing — a critical marker for chronic kidney disease — and is used by major U.S. health systems and insurers to enable remote monitoring at scale. Healthy.io also offers at-home wound care monitoring and UTI testing using the same smartphone-based platform.

Full profile
Pfizer logo

Pfizer

LeaderHealthcare Tech

Enterprise

Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.

AI VisibilityBeta
Overall Score
A93
Category Rank
#1 of 596
AI Consensus
80%
Trend
stable
Per Platform
ChatGPT
94
Perplexity
89
Gemini
94

About

Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.

Full profile

AI Visibility Head-to-Head

53
Overall Score
93
#272
Category Rank
#1
71
AI Consensus
80
stable
Trend
stable
48
ChatGPT
94
55
Perplexity
89
48
Gemini
94
58
Claude
92
48
Grok
98

Key Details

Category
Smartphone-Based Diagnostics
Enterprise
Tier
Challenger
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.